Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-60
SponsorSouth Valley University
About this trial
Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients of both sexes with positive slit skin smear for m.leprae .
Disqualifiers
Patients with hypersensitivity to sulfa .
Patients with hypersensitivity to clofazimine or rifampcin.
pregnant or lactating women.
Trial design
Design model
Parallel
Treatments tested in this trial
Dapsone
DrugTo evaluate the effect of the multi drug therapy in leprotic patients and their side effects and to assess the role of Rab 32 gene in leprosy prognosis and to know its association with the multi drug therapy.
Treatment groups
50 Participants
are divided into 2 treatment groupsGroup A: Group A: Leprosy PatientsActive comparator 1 intervention
Group B: Group B: Healthy PeopleActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Treatment of leprosy
About 40 of Participants With Treatment-Related Adverse Events as Assessed by measuring the of Rab 32 gene ( Rs2275606 ) polymorphism using real time PCR for Evaluation of the multi drug therapy on Leprotic Patients
Time frame
6 MonthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov